

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Fruquintinib

February 10, 2026

Therapeutic category

Other antitumor agents

Non-proprietary name

Fruquintinib

Safety measure

PRECAUTIONS should be revised.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
This English version is intended to be a reference material to provide convenience for users.
In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Revised language is underlined.

Current	Revision
<p>8. IMPORTANT PRECAUTIONS</p> <p>Proteinuria may occur. Urine protein should be monitored periodically before the start of and during administration of this drug.</p> <p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions (newly added)</p>	<p>8. IMPORTANT PRECAUTIONS</p> <p><u>Nephrotic syndrome</u> and proteinuria may occur. Urine protein should be monitored periodically before the start of and during administration of this drug.</p> <p>11. ADVERSE REACTIONS</p> <p>11.1 Clinically Significant Adverse Reactions</p> <p><u>Nephrotic syndrome</u></p>